CL2016001570A1 - Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas - Google Patents

Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas

Info

Publication number
CL2016001570A1
CL2016001570A1 CL2016001570A CL2016001570A CL2016001570A1 CL 2016001570 A1 CL2016001570 A1 CL 2016001570A1 CL 2016001570 A CL2016001570 A CL 2016001570A CL 2016001570 A CL2016001570 A CL 2016001570A CL 2016001570 A1 CL2016001570 A1 CL 2016001570A1
Authority
CL
Chile
Prior art keywords
activity
vortioxetine
treatment
depressive disorder
receptor antagonist
Prior art date
Application number
CL2016001570A
Other languages
English (en)
Spanish (es)
Inventor
Connie Sanchez Morillo
Gennady N Smagin
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52146489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016001570(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CL2016001570A1 publication Critical patent/CL2016001570A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2016001570A 2013-12-20 2016-06-17 Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas CL2016001570A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201300710 2013-12-20
DKPA201400590 2014-10-16

Publications (1)

Publication Number Publication Date
CL2016001570A1 true CL2016001570A1 (es) 2016-12-09

Family

ID=52146489

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001570A CL2016001570A1 (es) 2013-12-20 2016-06-17 Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas

Country Status (14)

Country Link
US (1) US10376506B2 (enExample)
EP (1) EP3082815B1 (enExample)
JP (1) JP6448645B2 (enExample)
KR (1) KR20160093025A (enExample)
CN (1) CN105828821B (enExample)
AU (1) AU2014368548B2 (enExample)
CA (1) CA2933733A1 (enExample)
CL (1) CL2016001570A1 (enExample)
ES (1) ES2694352T3 (enExample)
IL (1) IL246253A0 (enExample)
MX (1) MX368870B (enExample)
RU (1) RU2679661C1 (enExample)
SG (1) SG11201604944PA (enExample)
WO (1) WO2015091833A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190025556A (ko) * 2016-07-01 2019-03-11 하. 룬드벡 아크티에셀스카브 항우울 효과의 신속한 개시를 위한 보티옥세틴 투여 요법
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CA3118708A1 (en) 2018-11-06 2020-05-14 Purdue Pharma L.P. Compositions and methods for opioid antagonist delivery
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
US11998524B2 (en) 2022-03-07 2024-06-04 Janssen Pharmaceuticals, Inc. Forms of aticaprant
IL315415A (en) 2022-03-07 2024-11-01 Janssen Pharmaceuticals Inc The compositions containing eticarpant

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5013740A (en) 1990-03-22 1991-05-07 Hillel Glover Method for treating emotional numbness and coma
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
EP1353665A4 (en) 2000-12-21 2004-05-06 Mclean Hospital Corp Treatment of depression
US20030087896A1 (en) 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
HUP0401022A3 (en) * 2001-08-14 2006-11-28 Biotie Therapies Corp Method for the preparation of pharmaceutical compositions containing opioid antagonist for treating alcoholism or alcohol abuse
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
DK1485051T3 (da) * 2002-03-20 2008-09-08 Euro Celtique Sa Fremgangsmåde til indgivelse af buprenorphin til behandling af depression
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2009517393A (ja) * 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド 不安症の治療方法
CN101432011A (zh) * 2006-02-27 2009-05-13 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
WO2008066916A1 (en) 2006-11-30 2008-06-05 The Mclean Hospital Corporation Methods for the treatment of mood disorders
PT2001456E (pt) * 2006-04-04 2010-03-03 Emodys Gmbh Utilização de composições contendo antagonistas dos receptores opióides kappa no tratamento de distúrbios dissociativos
US20070259939A1 (en) * 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
CN102614179B (zh) 2006-06-16 2015-11-25 H.隆德贝克有限公司 作为用于治疗认知损伤的、具有结合的对血清素再吸收、5-ht3和5-ht1a活性的化合物的1-[2-(2，4-二甲基苯基硫烷基)-苯基]哌嗪
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
EA019331B1 (ru) 2009-05-25 2014-02-28 Х. Лундбекк А/С Получение налмефена гидрохлорида из налтрексона
WO2011020030A2 (en) * 2009-08-13 2011-02-17 The General Hospital Corporation Methods and compositions to prevent addiction
BR112012027794A2 (pt) 2010-04-30 2016-08-02 Takeda Pharmaceutical tablete entérico
RS55777B1 (sr) 2010-11-05 2017-07-31 H Lundbeck As Postupak za proizvodnju naltreksona
CN104955483A (zh) 2013-01-30 2015-09-30 法莫斯医疗公司 用低剂量药剂治疗抑郁症和其它疾病
JP6479766B2 (ja) 2013-04-17 2019-03-06 ハー・ルンドベック・アクチエゼルスカベット 不安障害患者の治療のためのナルメフェン
JP6416213B2 (ja) * 2013-04-17 2018-10-31 ハー・ルンドベック・アクチエゼルスカベット 気分障害患者の治療のためのナルメフェン

Also Published As

Publication number Publication date
WO2015091833A1 (en) 2015-06-25
JP2016540030A (ja) 2016-12-22
CN105828821B (zh) 2019-04-09
ES2694352T3 (es) 2018-12-20
MX2016007947A (es) 2016-09-09
AU2014368548A1 (en) 2016-06-30
EP3082815B1 (en) 2018-10-03
IL246253A0 (en) 2016-07-31
US10376506B2 (en) 2019-08-13
RU2679661C1 (ru) 2019-02-12
SG11201604944PA (en) 2016-07-28
CN105828821A (zh) 2016-08-03
AU2014368548B2 (en) 2019-09-19
RU2016123972A (ru) 2018-01-25
CA2933733A1 (en) 2015-06-25
KR20160093025A (ko) 2016-08-05
JP6448645B2 (ja) 2019-01-09
US20160310488A1 (en) 2016-10-27
MX368870B (es) 2019-10-21
EP3082815A1 (en) 2016-10-26

Similar Documents

Publication Publication Date Title
CL2016001570A1 (es) Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas
TR201902516T4 (tr) Glukagon-glp-1-gıp üçlü agonist bileşikleri.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
CL2015003440A1 (es) Composiciones de arni contra tmprss6 y métodos para su uso
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX2016015743A (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa.
UY34636A (es) Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso
CL2014003339A1 (es) Anticuerpo humanizado anti-trka con propiedades inhibitorias mejoradas; composición que lo comprende; y uso para tratar el dolor.
MX382747B (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas oncológicas y autoinmunitarias.
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
CL2016002873A1 (es) Composición farmacéutica para reducir el daño talámico.
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
HUE067221T2 (hu) IL-1béta inhibitor készítmény és annak alkalmazása
HRP20181536T1 (hr) Supstituirani piperidinil-tetrahidrokinolini i njihova uporaba kao antagonisti alfa-2c adrenoreceptora
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios
CL2016000325A1 (es) Antagonistas de vía para tratar trastornos del sueño por cambio de fase
BR112015016995A2 (pt) uso de agonistas de receptores alfa 7 nicotínico de acetilcolina para a facilitação do surgimento da anestesia geral
UY34829A (es) Nueva dosificación y formulación
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.